Complete remission of a primary cutaneous B cell lymphoma treated with intralesional recombinant interferon alpha-2a

Zénone, T; Catimel, G.; Barbet, N.; Clavel, M.

doi:10.1016/0959-8049(94)90101-5

Cited by 27 publications

(13 citation statements)

References 8 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In the present case we observed a complete response and a good tolerability of interferon monotherapy. This is in line with the experience described in other reports on PCBCLs (Tourani et al 1989;Zenone et al 1994;Wollina 1998) and MALT-associated lymphomas (Zinzani et al 1997).…”

Section: Discussionsupporting

confidence: 92%

Primary cutaneous marginal center lymphoma - complete remission induced by interferon α2a

Wollina

Hahnfeld²,

Kosmehl

1999

Journal of Cancer Research and Clinical Oncology

View full text Add to dashboard Cite

Marginal zone lymphoma (MZL) is a distinct entity among B-cell lymphomas. We report on a 53-year-old woman who developed disseminated primary cutaneous MZL with secondary lymph node involvement and perinodular spreading. The tumor cell phenotype was characterized as CD20/CD79a/kappa/lambda+/ bcl-2-positive, CD3/5/15/39/bcl-1-negative. Ki-67 was expressed by 20-35% of tumor cells. There was no evidence of systemic (including bone marrow) involvement. The diagnosis of MZL with plasmacellular differentiation (Stage IVa) was made. The patient was treated with interferon alpha2a injected s.c. at 9x10(6) U 3 days a week for 1 year. During this time the skin lesions completely disappeared. No evidence of lymph node or extracutaneous disease was found. The patient remains in complete remission. Side effects were only of grade I (WHO); the Karnovsky index was 90%. As shown for other types of primary cutaneous B-cell lymphoma, prolonged interferon alpha monotherapy may be effective in controlling the disease and/or inducing complete remission in MZL.

show abstract

Section: Discussionsupporting

confidence: 92%

Primary cutaneous marginal center lymphoma - complete remission induced by interferon α2a

Wollina

Hahnfeld²,

Kosmehl

1999

Journal of Cancer Research and Clinical Oncology

View full text Add to dashboard Cite

show abstract

“…46,[62][63][64] All 7 patients reached a CR. Two patients experiencing a clinical relapse were again successfully treated with a second course of IFN-␣.…”

Section: Interferon Alpha (Ifn-␣) Intralesionalmentioning

confidence: 99%

European Organization for Research and Treatment of Cancer and International Society for Cutaneous Lymphoma consensus recommendations for the management of cutaneous B-cell lymphomas

Senff¹,

Noordijk

Kim³

et al. 2008

Blood

406

405

View full text Add to dashboard Cite

“…Radiotherapy alone has been used in patients with localized B-cell PCNHL with the relapse rates ranging between 32% and 100% (3,(9)(10)(11). There are reports of intralesional administration of interferon alfa, cisplatin and bexarotene (tegretin) (11,12). Zenone et al presented one patient who had complete remission with intralesional interferon alfa ( 11).…”

Section: Discussionmentioning

confidence: 96%

“…It has included radiotherapy, surgical excision, combination chemotherapy or combined modality regimens (3,8). Radiotherapy alone has been used in patients with localized B-cell PCNHL with the relapse rates ranging between 32% and 100% (3,(9)(10)(11). There are reports of intralesional administration of interferon alfa, cisplatin and bexarotene (tegretin) (11,12).…”

Section: Discussionmentioning

confidence: 97%

Rituximab for primary cutaneous large B-cell non-Hodgkin's lymphoma of the scalp

Čolović¹,

Jurišić²,

Čolović³

2008

Arch Oncol

View full text Add to dashboard Cite

A 46-year-old man with a primary cutaneous large B-cell non-Hodgkin's lymphomas is reported. His mother died of gastric lymphoma and his sib brother is 20 years in a remission of T-cell lymphoma. He noticed the appearance of localized baldness and rash of the scalp 16 years before a hematological diagnosis was made. Diagnostic procedures performed in 2006 demonstrated progressive disease with crusted skin nodules (7x7.2cm) which exuded serous fluid. Histopathologcal and immunohistochemical results suggested the diagnosis of a primary cutaneous large B-cell non-Hodgkin's lymphoma. The patient was treated with rituximab and chemotherapy (protocol R-CHOP) and achieved a complete remission. A rather protracted indolent phase of disease, the familial history of lymphoma, and an excellent response to immunochemotherapy contributed to an unusual presentation of this patient's disease

show abstract

Complete remission of a primary cutaneous B cell lymphoma treated with intralesional recombinant interferon alpha-2a

Cited by 27 publications

References 8 publications

Primary cutaneous marginal center lymphoma - complete remission induced by interferon α2a

Primary cutaneous marginal center lymphoma - complete remission induced by interferon α2a

European Organization for Research and Treatment of Cancer and International Society for Cutaneous Lymphoma consensus recommendations for the management of cutaneous B-cell lymphomas

Rituximab for primary cutaneous large B-cell non-Hodgkin's lymphoma of the scalp

Contact Info

Product

Resources

About